Effects of D-003 (5-200 MG/KG), mixture of high molecular weight aliphatic acids from sugarcane wax, on bones and bone cell apoptosis in ovariectomized rats

International Journal of Tissue Reactions

Volumn 27, Issue 4, 2005, Pages 213-222

  Mendoza, S ^a   Noa, M ^a   Mas R ^a   Mendoza, N ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; D 003; PENTOBARBITAL; PREDNISOLONE; WAX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE CELL; CELL SURFACE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MIXTURE; FEMALE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOLECULAR WEIGHT; MORPHOMETRICS; NONHUMAN; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; RANDOMIZATION; RAT; STATISTICAL SIGNIFICANCE; SUGARCANE; TRABECULAR BONE;

ANIMALS; APOPTOSIS; BONE AND BONES; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; FEMALE; MOLECULAR WEIGHT; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; SACCHARUM; WAXES;

ANIMALIA; SACCHARUM HYBRID CULTIVAR;

EID: 30344454367     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Watts N. Osteoporosis: Prevention, detection and treatment. J. Med. Assoc. Ga, 86(3), 224, 1997.
2. Looker A.C., Johnston C.C., Wahner H.W., et al. Prevalence of low femoral bone density in older US women from NHANES III. J. Bone Miner. Res., 10, 796, 1995.
3. Bagi C., Ammann P., Rizzoli R., Miller S. Effect of estrogen deficiency on cancellous and cortical bone structure and strength of the femoral neck in rats. Calcif. Tissue Int., 61, 336, 1997.
4. Thompson D., Simmons H., Pirie C., Ke H. FDA guidelines and animal models for osteoporosis. Bone, 17, 125S, 1995.
5. Doggrell S.A. Present and future pharmacotherapy for osteoporosis. Drugs Today, 39, 633, 2003.
6. Delmas P. Treatment of postmenopausal osteoporosis. Lancet, 359, 2018, 2002.
7. Russell R.G., Rogers M.J., Frith S.C., et al. The pharmacology of biphosphonates and new insights into their mechanism of action. J. Bone. Min. Res., 14(Suppl. 2), 53, 1999.
8. Luckman S.P., Hughes D.E., Coxon F.P. et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res., 13, 581, 1998.
9. Fisher J.E., Halasy J.M., Masarachia P.J. et al. Alendronate mechanism of action: Inhibition of osteoclastogenesis and bone resorption are mimicked by lovastatin and blocked by geranylgeraniol. Bone, 23, S339, 1998.
10. van Beek E.R., Pieterman E., Cohen L., et al. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res. Commun., 255, 491, 1999.
11. van Beek E.R., Löwik C., van der Pluijm G., Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J. Bone Miner. Res., 14, 722, 1999.
12. Fisher J.E., Rogers M.J., Halasy J.M., et al. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA, 96, 133, 1999.
13. Manolagas S. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocrine Revs., 21, 115, 2000.
14. Bauer D.C. HMG-CoA reductase inhibitors and the skeleton: A comprehensive review. Osteopor. Int., 14, 273, 2003.
15. Maritz F.J., Conradie M.M. Hulley P.A., et al. Effect of statins on bone mineral density and bone. Histomorphometry in rodents. Arterioscler. Thromb. Vasc. Biol., 21, 1636, 2001.
16. Garrett I.R., Gutierrez G., Mundy G.R. Statins and bone formation. Curr. Pharm. Des., 7, 715, 2001.
17. Sugiyama M., Kodama T., Konishi K., et al. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun., 271, 688, 2000.
18. Parhami F., Morrow A., Balucan J., Tintut Y. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol., 17, 680, 1997.
19. Xu H., Watkins B., Seifert M. Vitamin E stimulates trabecular bone formation and alters epiphyseal cartilage morphometry. Calc.Tissue Int., 57, 293, 1995.
20. Mas R. D-003: A new substance with promising lipid modifying and pleiotropic effects for atherosclerosis management. Drugs Future, 29, 773, 2004.
21. Menéndez R., Más R., Amor A.M., et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol. Res., 44, 299, 2001.
22. Menéndez R., Más R., Pérez J., et al. Oral administration of D-003, a mixture of very long chain saturated fatty acids, prevents casein-induced endogenous hypercholesterolemia in rabbits. Can. J. Physiol. Pharmacol., 82, 22, 2003.
23. Gámez R., Mendoza S., Mas R., et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr. Ther. Res. Clin. Exp., 61, 8, 2000.
24. Mendoza S., Gamez R., Mas R., et al. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits. Int. J. Tissue React., XXV, 81, 2003.
25. Castaño G., Mas R., Fernández L., et al. Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound, in healthy volunteers. Drugs in R&D, 3, 337, 2002.
26. Castaño G., Menéndez R., Mas R., et al. Effects of D-003 on lipid profile and lipid peroxidation in healthy volunteers. Clin. Drug Invest., 23, 193, 2003.
27. Castaño G., Mas R., Fernández L., et al. Effects of D-003 (5-40 mg/day) on lipid profile of patients with Type II hypercholesterolemia: A Phase II clinical study. Clin. Drug Invest., 23, 789, 2003.
28. Menéndez R., Mas R., Pérez Y., et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty acids. Can. J. Physiol. Pharmacol., 80, 13, 2002.
29. Noa M., Más R., Mendoza S., Gámez R., Mendoza N. Effects of D-003, a mixture of high molecular weight aliphatic acids from sugar cane wax, on bones from ovariectomized rats. Drugs Exptl. Clin. Res., 30, 35, 2004.
30. Mendoza S., Noa M., Mas R. A comparison of the effects of D-003, a mixture of high molecular weight aliphatic acids from sugarcane wax, and pravastatin, on bones and osteoclast apoptosis of ovariectomized rats. Drugs Exptl. Clin. Res., 2005 (in press).
31. Noa M., Mendoza S., Más R., Mendoza N., León F. Effects of D-003, a mixture of very high molecular weight aliphatic acids from sugar cane wax, on prednisolone-induced osteoporosis in Sprague Dawley rats. Drugs in R&D, 5, 281, 2004.
32. Pytlik M., Janiec W., Misiarz-Myrta M., Gubala I. Effects of simvastatin on the development of osteopenia caused by ovariectomy in rats. Pol. J. Pharmacol., 55, 63, 2003.
33. Mosekilde L., Danielsen C., Knudsen B. The effect of aging and ovariectomy on the vertebral bone mass and biochemical properties of mature rats. Bone, 14, 1, 1993.
34. Parfitt A., Drezner M., Glorieux F., et al. Bone histomorphometry. Standardization of nomenclature, symbols, and units. J. Bone Min. Res., 2, 595, 1987.
35. Coro R.M., Borrajero I. DIGIPAT. Un sistema cubano para morfometría de imágenes. Rev. Latinoam. Patol., 39, 9, 1996.
36. Sanders E.J. Method for detecting apoptotic cells in tissues. Histol. Histopathol., 12, 1169, 1997.
37. Gohel A., McCarthy M.B., Gronowicz G. Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinol., 140, 5339, 1999.
38. Weinstein R., Jilka R., Parfitt M., Manolagas S. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J. Clin. Invest., 102, 274, 1998.
39. Weinstein R., Manolagas S. Apoptosis and osteoporosis. Am. J. Med., 108, 153, 2000.
40. Plotkin L., Weinstein R., Parfitt A.M. Prevention of osteocyte and osteoblast apoptosis by biphosphonates and calcitonin. J. Clin. Invest., 104, 1363, 1999.